© Copyright 2022 Imageens | Artfun+. All rights reserved.
Artfun+ has emerged as cutting-edge medical technology, revolutionizing the assessment and management of cardiovascular health. Developed by Imageens, this breakthrough tool offers new MRI cardiovascular imaging scores that assist physicians in predicting and detecting the earliest signs of cardiovascular diseases across large at-risk and asymptomatic patient populations..
The core of its biomarker is the measurement of ascending aortic distensibility (AAD score) by MRI, which measures the stiffness of the central arteries. It is the strongest predictor of CV events at 8.5 years for intermediate/low-risk patients using traditional risk factors .
This Artfun+ biomarker holds promise in diverse clinical applications, addressing unmet needs in various medical domains. It has powered a series of +75 publications with leading cardiovascular healthcare professionals, increasing the understanding of CV diseases.(link).
In this article, we explore the multiple potential clinical applications of Artfun+ biomarkers (cardiovascular scores) in addressing critical challenges across several medical fields.
The first application of Artfun+ biomarker lies in cardiovascular primary prevention. By providing a comprehensive analysis of a patient’s cardiovascular age and risk, this technology empowers healthcare professionals to implement personalized prevention strategies.
Thanks to the MESA study, where Artfun biomarkers were validated on 3,675 patients followed over 8.5 years, it was shown how they predicted the risk of mortality and hard cardiovascular disease 8.5 years in advance, based on the analysis of the patient’s ascending aortic stiffness.
Armed with valuable insights, patients can make informed lifestyle choices to mitigate their risk of cardiovascular diseases such as hypertension, atherosclerosis, and heart attacks. The ability to monitor and track changes over time offers a proactive approach to maintaining heart health, potentially reducing the burden of heart-related ailments in the long run.
Artfun+ biomarkers powered a predictive clinical decision tool for cardiovascular age & risk analysis called Cardioinspect (Discover Cardioinspect link). Cardioinspect helps cardiologists and clinics to start and monitor cardiovascular prevention by providing a personal report that screens the cardiovascular age and detects the earliest signs of CV disease based on our proprietary data.
For individuals diagnosed with premature coronary artery diseases (CAD), predicting the recurrence of ischemic events is of paramount importance. Artfun+ presents a powerful solution, enabling clinicians to predict the recurrence of ACS as validated in the AFiji study on patients with an ACS < 45 years old, followed up for an average of 3 years (link).
By measuring the AAD score, the technology assists in predicting and preventing recurrent ischemic events, significantly improving patient outcomes and quality of life.
Aortic aneurysms pose a severe threat to patients’ lives, and timely intervention is crucial to prevent catastrophic consequences. Artfun+ plays a pivotal role in predicting the risk of aortic rupture, empowering doctors to make informed decisions about the optimal timing for preventive surgery. By closely monitoring patients’ aortic health, clinicians can intervene proactively, potentially saving lives and minimizing complications.
Learn more about how Artfun+ biomarkers can inform decision-making and enable accurate individual risk reclassification in aortic aneurysms (link).
Aortic aneurysms pose a severe threat to patients’ lives, and timely intervention is crucial to prevent catastrophic consequences. Artfun+ plays a pivotal role in predicting the risk of aortic rupture, empowering doctors to make informed decisions about the optimal timing for preventive surgery. By closely monitoring patients’ aortic health, clinicians can intervene proactively, potentially saving lives and minimizing complications.
Major surgeries inherently carry a risk of cardiac events, especially in intermediate-risk patients. Artfun+ provides an essential preoperative cardiac risk assessment, enabling clinicians to gauge patients’ cardiac health and identify potential vulnerabilities. Armed with this knowledge, healthcare professionals can implement targeted interventions, optimize perioperative care, and prevent cardiac events during and after major surgeries.
Carotid stenosis, a condition characterized by the narrowing of the carotid arteries, can lead to serious complications like atherosclerotic plaque detachment. Artfun+ facilitates early detection of this risk, allowing doctors to make timely decisions about intervention and surgery. By minimizing the risk of plaque detachment, the technology plays a pivotal role in preventing strokes and improving patient outcomes.
As the world grapples with the aftermath of the COVID-19 pandemic, understanding its effects on cardiac health is paramount. Artfun+ offers a novel way to assess recovered COVID-19 patients, providing clinicians with valuable insights into potential cardiac implications. By monitoring cardiac changes over time, clinicians can optimize treatment strategies, leading to improved outcomes and a better quality of life for recovered patients.
Artfun+ represents a groundbreaking technological advancement with vast potential in various unmet medical markets. Beyond monitoring cardiovascular prevention, its applications extend to predicting recurrent ischemic events in premature CAD, aiding in aortic aneurysm management, preoperative cardiac risk assessment, predicting risks in carotid stenoses, and assessing recovered COVID-19 patients. The versatility of Artfun+ empowers clinicians to make informed decisions, optimize patient care, and potentially revolutionize the landscape of preventive and interventional medicine. As research and development in medical imaging technologies continue to evolve, Artfun+ is poised to remain at the forefront of advancing healthcare, improving patient outcomes, and saving lives.”